BR0306309A - Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1 - Google Patents

Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1

Info

Publication number
BR0306309A
BR0306309A BR0306309-7A BR0306309A BR0306309A BR 0306309 A BR0306309 A BR 0306309A BR 0306309 A BR0306309 A BR 0306309A BR 0306309 A BR0306309 A BR 0306309A
Authority
BR
Brazil
Prior art keywords
disorders
treatment
decan
useful
triazaospiro
Prior art date
Application number
BR0306309-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Kathleen Battista
Gilles Bignan
Peter J Connolly
Allen B Reitz
Tina Morgan Ross
Malcolm Scott
Steven A Middleton
Michael Orsini
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978719&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0306309(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR0306309A publication Critical patent/BR0306309A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BR0306309-7A 2002-09-09 2003-09-05 Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1 BR0306309A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40913402P 2002-09-09 2002-09-09
PCT/US2003/027956 WO2004022558A2 (en) 2002-09-09 2003-09-05 Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders

Publications (1)

Publication Number Publication Date
BR0306309A true BR0306309A (pt) 2004-10-19

Family

ID=31978719

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0306309-7A BR0306309A (pt) 2002-09-09 2003-09-05 Derivados de 1,3,8-triazaespiro[4.5]decan-4-ona substituìda com hidroxialquila úteis para o tratamento de distúrbios mediados pelo receptor orl-1

Country Status (19)

Country Link
US (3) US7081463B2 (cg-RX-API-DMAC7.html)
EP (1) EP1601674B1 (cg-RX-API-DMAC7.html)
JP (1) JP4712384B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050043935A (cg-RX-API-DMAC7.html)
CN (1) CN100402529C (cg-RX-API-DMAC7.html)
AR (1) AR041205A1 (cg-RX-API-DMAC7.html)
AU (1) AU2003268512A1 (cg-RX-API-DMAC7.html)
BR (1) BR0306309A (cg-RX-API-DMAC7.html)
CA (1) CA2498275C (cg-RX-API-DMAC7.html)
CL (1) CL2003001814A1 (cg-RX-API-DMAC7.html)
EA (1) EA009369B1 (cg-RX-API-DMAC7.html)
MX (1) MXPA05002622A (cg-RX-API-DMAC7.html)
NO (1) NO20051743L (cg-RX-API-DMAC7.html)
NZ (1) NZ538307A (cg-RX-API-DMAC7.html)
PL (1) PL377047A1 (cg-RX-API-DMAC7.html)
RS (1) RS20050208A (cg-RX-API-DMAC7.html)
TW (1) TWI296627B (cg-RX-API-DMAC7.html)
WO (1) WO2004022558A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502836B (cg-RX-API-DMAC7.html)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
ZA200510329B (en) * 2003-05-23 2007-04-25 Zealand Pharma As Triaza-spiro compounds as nociceptin analogues and uses thereof
AR046756A1 (es) 2003-12-12 2005-12-21 Solvay Pharm Gmbh Derivados de hidronopol como agonistas de receptores orl-1 humanos.
US20060178390A1 (en) * 2004-08-02 2006-08-10 Alfonzo Jordan 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
ATE488519T1 (de) 2005-09-28 2010-12-15 Hoffmann La Roche Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten
TW200819457A (en) * 2006-08-30 2008-05-01 Actelion Pharmaceuticals Ltd Spiro antibiotic derivatives
CN103202840B (zh) * 2006-11-28 2015-02-11 詹森药业有限公司 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐
CN101616669B (zh) * 2006-11-28 2013-05-29 詹森药业有限公司 制备治疗酒精滥用、成瘾和依赖的药物
EP2150552B1 (en) * 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
US20100076003A1 (en) * 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
US10118918B2 (en) 2012-12-21 2018-11-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9365555B2 (en) 2012-12-21 2016-06-14 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9604930B2 (en) 2012-12-21 2017-03-28 Epizyme, Inc. Tetrahydro- and dihydro-isoquinoline PRMT5 inhibitors and uses thereof
JP2016505002A (ja) 2012-12-21 2016-02-18 エピザイム,インコーポレイティド ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するprmt5阻害剤およびその使用
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環(4.5)癸烷衍生物
AU2015301196A1 (en) 2014-08-04 2017-01-12 Epizyme, Inc. PRMT5 inhibitors and uses thereof
MX381417B (es) 2014-08-28 2025-03-12 Asceneuron Sa Inhibidores de glucosidasa.
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN122562777A (zh) * 2015-12-02 2026-08-14 阿斯特来亚治疗有限责任公司 哌啶基痛敏肽受体化合物
JP6971999B2 (ja) 2016-02-25 2021-11-24 エースニューロン・ソシエテ・アノニム ピペラジン誘導体の酸付加塩
CN108884077A (zh) 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
US11261183B2 (en) 2016-02-25 2022-03-01 Asceneuron Sa Sulfoximine glycosidase inhibitors
JP2019506430A (ja) 2016-02-25 2019-03-07 エースニューロン・ソシエテ・アノニム グリコシダーゼ阻害剤
US11213525B2 (en) 2017-08-24 2022-01-04 Asceneuron Sa Linear glycosidase inhibitors
RU2764243C2 (ru) 2017-09-22 2022-01-14 ДЖУБИЛАНТ ЭПИПЭД ЭлЭлСи Гетероциклические соединения в качестве ингибиторов PAD
CN111225915B (zh) 2017-10-18 2023-03-07 朱比兰特埃皮帕德有限公司 作为pad抑制剂的咪唑并吡啶化合物
US11629135B2 (en) 2017-11-06 2023-04-18 Jubilant Prodell Llc Pyrimidine derivatives as inhibitors of PD1/PD-L1 activation
RS65576B1 (sr) 2017-11-24 2024-06-28 Jubilant Episcribe Llc Heterociklična jedinjenja kao inhibitori prmt5
CN112105610B (zh) 2018-03-13 2024-01-26 朱比连特普罗德尔有限责任公司 作为pd1/pd-l1相互作用/活化的抑制剂的双环化合物
US11795165B2 (en) 2018-08-22 2023-10-24 Asceneuron Sa Tetrahydro-benzoazepine glycosidase inhibitors
CA3110032A1 (en) 2018-08-22 2020-02-27 Asceneuron S.A. Succinate and fumarate acid addition salts of piperazine derivatives
US12016852B2 (en) 2018-08-22 2024-06-25 Asceneuron Sa Pyrrolidine glycosidase inhibitors
WO2020039029A1 (en) * 2018-08-22 2020-02-27 Asceneuron S. A. Spiro compounds as glycosidase inhibitors

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US677421A (en) * 1900-10-19 1901-07-02 Kate Hatch Mcrae Cake-beater.
US3155699A (en) * 1960-03-30 1964-11-03 Mobay Chemical Corp Purification of isocyanates by reduction of the hydrolyzable chlorine and acid content
US3155670A (en) * 1962-06-22 1964-11-03 Res Lab Dr C Janssen N V 1-oxo-2, 4, 8, triaza-spiro (4, 5) decanes
US3161644A (en) * 1962-06-22 1964-12-15 Res Lab Dr C Janssen N V 1-benzyl-4-substituted piperidines
US3238216A (en) 1963-06-20 1966-03-01 Res Lab Dr C Janssen N V Substituted 1, 3, 8-triaza-spiro (4, 5) decanes
US3839340A (en) * 1968-09-27 1974-10-01 Fmc Corp Substituted 1,3,8-triazaspiro{8 4.5{9 decanes
US3629267A (en) * 1968-10-28 1971-12-21 Smith Kline French Lab Benzoheterocyclicalkyl derivatives of 4-(2-keto -1-benzimidazolinyl)-piperidine 4-(2-keto - 1 - benzimidazolinyl) -1 2 3 6 tetrahydropyridine 1 - phenyl - 1 3 8-triazaspiro(4 5)decan - 4 - one and 2 4 9-triazaspiro(5 5)undecan-1 3 5-trione
US3859340A (en) * 1970-09-09 1975-01-07 Squibb & Sons Inc ' -methylfluorene-2-acetic acid
US4020072A (en) * 1976-05-04 1977-04-26 E. R. Squibb & Sons, Inc. 5-Aminomethyl-1H-pyrazolo[3,4-b]pyridines
JPS54109983A (en) * 1978-02-13 1979-08-29 Sumitomo Chem Co Ltd Novel spiroamine derivative and its preparation
US4329363A (en) * 1978-09-08 1982-05-11 Merck & Co., Inc. Substituted mercapto acid amides and their use
US4526896A (en) * 1978-12-26 1985-07-02 Riker Laboratories, Inc. Tetrazol-5-yl 2-nitro-3-phenylbenzofurans and antimicrobial use thereof
US4329353A (en) * 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
JPS57212180A (en) * 1981-06-19 1982-12-27 Yoshitomi Pharmaceut Ind Ltd Tetrahydrofuran(thiophene) compound
WO1988000190A1 (en) 1986-06-25 1988-01-14 Massachusetts Institute Of Technology Optically active derivatives of glycidol
IL96507A0 (en) 1989-12-08 1991-08-16 Merck & Co Inc Nitrogen-containing spirocycles and pharmaceutical compositions containing them
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4135473A1 (de) 1991-10-28 1993-04-29 Bayer Ag Triazaspirodecanon-methylchromane
WO1993012789A1 (en) 1991-12-27 1993-07-08 Beth Israel Hospital Use of spiperone or spiperone derivatives as immunosuppressant agents
FR2708606B1 (fr) 1993-07-30 1995-10-27 Sanofi Sa Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
JPH11500100A (ja) 1993-09-09 1999-01-06 サイオス ノバ インコーポレイテッド 偽ペプチドおよび非ペプチドブラジキニンレセプターアンタゴニスト
US5739336A (en) 1995-06-23 1998-04-14 Syntex (U.S.A.) Inc. 1,3,8-triaza- and 3,8-diaza-1-oxaspiro 4,5! decane derivatives
US5821219A (en) 1995-08-11 1998-10-13 Oregon Health Sciences University Opioid antagonists and methods of their use
NZ326874A (en) 1996-03-29 2000-01-28 Pfizer 6-phenylpyridyl-2-amine derivatives
CA2226058C (en) 1997-01-30 2008-01-29 F. Hoffmann-La Roche Ag 8-substituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives
US6013652A (en) * 1997-12-04 2000-01-11 Merck & Co., Inc. Spiro-substituted azacycles as neurokinin antagonists
SI0921125T1 (en) * 1997-12-05 2002-04-30 F. Hoffmann-La Roche Ag 1,3,8-Triazaspiro(4,5)decan-4-on derivatives
DE69803653T2 (de) * 1997-12-05 2002-08-29 F. Hoffmann-La Roche Ag, Basel 1,3,8-Triazaspiro[4,5]decan-4-on-derivate
JP2002515503A (ja) * 1998-05-18 2002-05-28 ノボ ノルディスク アクティーゼルスカブ オピオイド受容体のサブタイプへの高い親和性を有する新規1,3,8−トリアザスピロ〔4,5〕デカノン
US6277991B1 (en) * 1998-05-18 2001-08-21 Novo Nordisk A/S 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
ES2162503T3 (es) 1998-06-12 2001-12-16 Hoffmann La Roche Derivados diaza-espiro(3,5)nonanos.
WO1999065494A1 (en) * 1998-06-15 1999-12-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
ID29137A (id) * 1998-07-27 2001-08-02 Schering Corp Ligan-ligan afinitas tinggi untuk reseptor nosiseptin orl-1
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
EP0997464B1 (en) * 1998-10-23 2005-02-16 Pfizer Inc. 1,3,8-Triazaspiro[4,5] decanone compounds as orl1-receptor agonists
JP2002530377A (ja) 1998-11-20 2002-09-17 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ Nk−3およびnk−2受容体アンタゴニストとしてのキノリン−4−カルボキシアミド誘導体
JP2000169476A (ja) 1998-12-09 2000-06-20 Banyu Pharmaceut Co Ltd 4−オキソイミダゾリジン−5−スピロ−含窒素複素環式化合物
AU1382901A (en) 1999-11-17 2001-05-30 Novo Nordisk A/S Novel triazaspirodecanones with high affinity for opioid receptor subtypes
DE19956598A1 (de) 1999-11-25 2001-06-13 Bosch Gmbh Robert Ventil zum Steuern von Flüssigkeiten
JP3989247B2 (ja) 1999-12-06 2007-10-10 ユーロ−セルティーク エス.エイ. ノシセプチン受容体親和性を有するトリアゾスピロ化合物
JP2005231995A (ja) * 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト/アンタゴニストとして有用なスピロ化合物
GB0003224D0 (en) 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2001096337A1 (en) 2000-06-14 2001-12-20 Banyu Pharmaceutical Co.,Ltd 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds
MXPA03009239A (es) 2001-04-10 2004-11-12 Johnson & Johnson Derivados de 1,3,8-triazapiro[4,5]decan-4-ona utiles para el tratamiento de trastornos mediados por el receptor orl-1.
CN1516584A (zh) 2001-04-18 2004-07-28 ŷ�����ǹɷ����޹�˾ 螺吡唑化合物
US20030078278A1 (en) * 2001-06-26 2003-04-24 Pfizer Inc. Spiropiperidine compounds as ligands for ORL-1 receptor
CA2454785C (en) * 2001-07-23 2010-09-07 Banyu Pharmaceutical Co., Ltd. 4-oxoimidazolidine-2-spiropiperidine derivatives
US20040014955A1 (en) * 2001-12-17 2004-01-22 Carlos Zamudio Identification of essential genes of cryptococcus neoformans and methods of use
EP1470126A1 (en) * 2002-01-28 2004-10-27 Pfizer Inc. N-substituted spiropiperidine compounds as ligands for orl-1 receptor
JP2005517007A (ja) 2002-02-07 2005-06-09 アクシス・ファーマスーティカルズ ヒストンデアセチラーゼ阻害剤としての新規二環式ヒドロキサメート
AU2003268512A1 (en) 2002-09-09 2004-03-29 Janssen Pharmaceutica N.V. Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
WO2005016913A1 (en) 2003-08-19 2005-02-24 Pfizer Japan, Inc. Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders
AU2004309419A1 (en) 2003-12-23 2005-07-14 Arena Pharmaceuticals, Inc. Novel spiroindoline or spiroisoquinoline compounds, methods of use and compositions thereof
US7879834B2 (en) 2004-08-19 2011-02-01 Vertex Pharmaceuticals Incorporated Spiroindoline modulators of muscarinic receptors
CA2581150A1 (en) 2004-09-17 2006-03-30 Osi Pharmaceuticals, Inc. (spirocyclylamido) aminothiophene compounds as c-kit proto- oncogene inhibitors
EP2522669B1 (en) * 2005-06-02 2016-12-28 Janssen Pharmaceutica NV 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators
CN101616669B (zh) 2006-11-28 2013-05-29 詹森药业有限公司 制备治疗酒精滥用、成瘾和依赖的药物
EP2150552B1 (en) 2007-04-09 2013-01-02 Janssen Pharmaceutica NV 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the orl-i receptor for the treatment of anxiety and depression
US20100076003A1 (en) 2008-09-19 2010-03-25 Kathleen Battista 5-oxazolidin-2-one substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful as orl-1 receptor modulators

Also Published As

Publication number Publication date
KR20050043935A (ko) 2005-05-11
EP1601674B1 (en) 2012-08-08
CL2003001814A1 (es) 2005-02-11
CA2498275A1 (en) 2004-03-18
RS20050208A (sr) 2007-08-03
US20090124614A1 (en) 2009-05-14
EA200500331A1 (ru) 2005-08-25
US7081463B2 (en) 2006-07-25
JP4712384B2 (ja) 2011-06-29
TWI296627B (en) 2008-05-11
WO2004022558A3 (en) 2004-05-21
AU2003268512A1 (en) 2004-03-29
NZ538307A (en) 2008-04-30
EP1601674A2 (en) 2005-12-07
US8778956B2 (en) 2014-07-15
MXPA05002622A (es) 2005-09-08
CN1694883A (zh) 2005-11-09
AR041205A1 (es) 2005-05-11
US20060030577A1 (en) 2006-02-09
WO2004022558A2 (en) 2004-03-18
PL377047A1 (pl) 2006-01-23
JP2006500393A (ja) 2006-01-05
US7582649B2 (en) 2009-09-01
EA009369B1 (ru) 2007-12-28
CN100402529C (zh) 2008-07-16
TW200418857A (en) 2004-10-01
CA2498275C (en) 2011-07-12
US20040142955A1 (en) 2004-07-22
ZA200502836B (en) 2006-06-28
NO20051743L (no) 2005-05-18

Similar Documents

Publication Publication Date Title
WO2004022558A3 (en) Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of orl-1 receptor mediated disorders
Yang et al. A cell-based target engagement assay for the identification of cereblon E3 ubiquitin ligase ligands and their application in HDAC6 degraders
ATE203023T1 (de) Tropanderivate, deren herstellung und verwendung
Molinari et al. Oligosaccharyltransferase-subunit mutations in nonsyndromic mental retardation
Chen et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain
JP6550132B2 (ja) Cd38阻害剤及び治療の方法
BRPI0408910A (pt) composto, composição farmacêutica e métodos para a profilaxia ou o tratamento de doenças ou condições e para a produção de uma composição farmacêutica
ATE402935T1 (de) Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen rezeptors zur behandlung von gastrointestinalen erkrankungen
CY1112418T1 (el) Παραγωγα σουλφονυλοπυραζολινο-1-καρβοξαμιδινης ως 5-ητ6 ανταγωνιστες
BRPI0607456A2 (pt) derivados de oxindol como agonistas do receptor 5ht4
Chenard et al. Quinazolin-4-one α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonists: Structure− Activity Relationship of the C-2 Side Chain Tether
BRPI0411661A (pt) derivados de n-fenil-piperazina e métodos de profilaxia ou tratamento de doenças associadas com o receptor 5ht 2c
Kolanos et al. Binding of isotryptamines and indenes at h5-HT6 serotonin receptors
ATE496026T1 (de) 1,3-disubstituierte 4-methyl-1 h-pyrrol-2- carbonsäureamide und ihre verwendung zur herstellung von arzneimitteln
Pietrancosta et al. Novel cyclized Pifithrin-α p53 inactivators: synthesis and biological studies
Herrero et al. 2-Oxopiperazine-based γ-turn conformationally constrained peptides: Synthesis of CCK-4 analogues
Bowser et al. A 1, 3-Diaza-Claisen rearrangement that affords guanidines
Maki et al. Direct comparison of A-and T-strand minor groove interactions in DNA curvature at A tracts
Li et al. Synthesis and biological evaluation of p38α kinase-targeting dialkynylimidazoles
ATE334680T1 (de) 4-aminopiperidin-derivate, verfahren zur herstellung und ihre verwendung als arzneimittel
Lee et al. Gender effect of catechol-O-methyltransferase Val158Met polymorphism on suicidal behavior
Raza et al. Pharmacological Evaluation and Docking Studies of 3‐Thiadiazolyl‐and Thioxo‐1, 2, 4‐triazolylcoumarin Derivatives as Cholinesterase Inhibitors
Ding et al. DNA damage and interstrand cross-link formation upon irradiation of aryl iodide C-nucleotide analogues
Haadsma-Svensson et al. C-9 and N-substituted analogs of cis-(3aR)-(-)-2, 3, 3a, 4, 5, 9b-hexahydro-3-propyl-1H-benz [e] indole-9-carboxamide: 5-HT1A receptor agonists with various degrees of metabolic stability
Trabocchi et al. Synthesis of a constrained tricyclic scaffold based on trans-4-hydroxy-L-proline

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE A 8A ANUIDADE.